Company
Headquarters: Stockholm, Sweden
Employees: 8
kr1.32 Billion
SEK as of July 1, 2024
US$124.4 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
Infant Bacterial Therapeutics AB has the following listings and related stock indices.
Stock: OMX: IBT.B wb_incandescent
Stock: XSTU: 9IB wb_incandescent